Phase III Confirmatory Study in Erythropoietic Protoporphyria

PHASE3CompletedINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions
Erythropoietic Protoporphyria
Interventions
DRUG

Afamelanotide

One 16mg subcutaneous implant every 2 months for 6 months.

DRUG

Placebo

One placebo subcutaneous implant every 2 months for 6 months

Trial Locations (7)

10029

Mt. Sinai, New York

29203

Carolina's Medical Center Cannon Research, Charlotte

35294

University of Alabama, Birmingham

48202

Henry Ford Medical Center, Detroit

77555

University of Texas, Galveston

84112

University of Utah, Salt Lake City

94143

University of California, San Francisco, San Francisco

All Listed Sponsors
lead

Clinuvel Pharmaceuticals Limited

INDUSTRY